A Phase 1 interventional study of alisertib in Advanced Malignancies, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multicenter, dose escalation, phase 1 study of MLN8237 in adult participants with advanced malignancies (excluding those with primary bone marrow involvement, such as leukemias and multiple myeloma).
The drug tested in this study is called alisertib. Alisertib is being tested to treat people who have advanced malignancies. This study determined the dose-limiting toxicity, maximum tolerated dose, safety and pharmacokinetics (how the drug moves through the body) for alisertib when given once or twice a day for 7 to 21 days.
This open label study enrolled 59 patients. Participants were enrolled in one of 10 dose escalation arms:
All participants received treatment until their disease progressed or they experienced unacceptable alisertib-related toxicity.
This multi-center trial was conducted in Spain. The overall time to participate in this study was 730 days. Participants made multiple visits to the clinic, including a final visit 30 days after receiving their last dose of alisertib for a follow-up assessment.
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted before Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alisertib 5 mg, capsules, orally, once daily (QD) for 7 days (D) followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 3 cycles).
Drug: alisertib
Alisertib 80 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 4 cycles).
Drug: alisertib
Alisertib 150 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).
Drug: alisertib
Alisertib 50 mg, capsules, orally, twice daily (BID) for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 29 cycles).
Drug: alisertib
Alisertib 60 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).
Drug: alisertib
Alisertib 75 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 8 cycles).
Drug: alisertib
Alisertib 100 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 21 cycles).
Drug: alisertib
Alisertib 50 mg, capsules, orally, QD for 14 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 25 cycles).
Drug: alisertib
Alisertib 50 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 10 cycles).
Drug: alisertib
Alisertib 70 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
Drug: alisertib
Alisertib (MLN8237) capsules
Also known as: MLN8237
Number of Participants With Dose-Limiting Toxicity (DLT)
DLT was evaluated using the National Cancer Institutes Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0; defined as any of the following events related to alisertib therapy: 1. Grade 4 neutropenia lasting for ≥7 consecutive days during recovery 2. Grade 4 neutropenia with fever and/or infection 3. Confirmed platelet count \<25,000/mm\^3 4. ≥Grade 3 nausea and/or emesis despite the use of an antiemetic prophylaxis 5. ≥Grade 3 diarrhea that occurred despite therapy with loperamide 6. Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (\< 1 week) Grade 3 fatigue 7. Treatment delay of \>1 week because of a failure of adequate hematologic or nonhematologic recovery from the previous cycle of treatment. 8. Other alisertib-related nonhematologic toxicities ≥ Grade 2 that, in the opinion of the investigator, required a dose reduction or discontinuation of therapy with alisertib.
Time frame: First dose through 30 days following the last dose of study drug (up to 730 days)
Maximum Tolerated Dose (MTD) of Alisertib
The MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 participants.
Time frame: Signing of the Informed Consent through 30 days following the last dose of study drug (up to 730 days)
Cmax: Maximum Observed Concentration for Alisertib 7 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Day 7
Tmax: Time of First Occurrence of Cmax for Alisertib 7 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Day 7
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 7 Day Dosing
Time frame: Cycle1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Day 7
Terminal Half-Life (t1/2) for Alisertib 7 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7 or 8 (BID arms)
Accumulation Ratio (Rac) for Alisertib 7 Day Dosing
Rac for Day 7=AUCt Day 7/AUCt Day 1.
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7
Peak/Trough Ratio for Aliserib 7 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7
CLss/F: Apparent Oral Clearance at Steady State 7 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7
Cmax: Maximum Observed Concentration for Alisertib 14 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
Tmax: Time of First Occurrence of Cmax for Alisertib 14 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 14 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
Terminal Half-Life (t1/2) for Alisertib 14 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
Accumulation Ratio (Rac) for Alisertib 14 Day Dosing
Rac for Day 7=AUCt Day 7/AUCt Day 1. Rac for Day 14=AUCt Day 7/AUCt Day 1.
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
Peak/Trough Ratio for Aliserib 14 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
CLss/F: Apparent Oral Clearance at Steady State 14 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
Cmax: Maximum Observed Concentration for Alisertib 21 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21
Tmax: Time of First Occurrence of Cmax for Alisertib 21 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 21 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21
Terminal Half-Life (t1/2) for Alisertib 21 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 21
Accumulation Ratio (Rac) for Alisertib 21 Day Dosing
Rac for Day 7=AUCt Day 7/AUCt Day 1. Rac for Day 14=AUCt Day 7/AUCt Day 1. Rac for Day 21=AUCt Day 21/AUCt Day 1.
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21
Peak/Trough Ratio for Aliserib 21 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21
CLss/F: Apparent Oral Clearance at Steady State 21 Day Dosing
Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21
Change From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 7 Day Dosing
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
Time frame: Cycle 1: Pre-dose (Baseline) and Day 1, 6 hours post-dose; Day 7, 6 and 24 hours post-dose.
Change From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 14 Day Dosing
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
Time frame: Cycle 1: Pre-dose (Baseline) and Day 1 and 7, 6 hours post-dose; Day 14, 6 and 24 hours post-dose
Change From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 21 Day Dosing
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
Time frame: Cycle 1: Pre-dose (Baseline) and Day 7, 14 and 21, 6 hours post-dose
Change From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 7 Day Dosing
Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement.
Time frame: Cycle 1: Day 1, 6 hours post-dose; Days 7 6 and 24 hours post-dose; Day 21: 6 hours post-dose
Change From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 14 Day Dosing
Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement.
Time frame: Cycle 1: Pre-dose (Baseline) and Day 1, 6 hours post-dose; Days 7 and 14, 6 and 24 hours post-dose
Change From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 21 Day Dosing
Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement.
Time frame: Cycle 1: Pre-dose (Baseline) and Day 1, 6 hours post-dose; Days 7 and 14, 6 and 24 hours post-dose; Day 21: 6 hours post-dose
Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 7 Day Dosing
Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement.
Time frame: Cycle 1: Pre-dose (Baseline) and Days 1 and 7, 6 hours post-dose
Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 14 Day Dosing
Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement.
Time frame: Cycle 1: Pre-dose (Baseline) and Day 7, 6 hours post-dose
Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 21 Day Dosing
Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement.
Time frame: Cycle 1: Pre-dose (Baseline) and Days 7 and 21, 6 hours post-dose
Percentage of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1
A blood sample was collected prior to alisertib dosing for the purpose of genotyping for polymorphisms in UGT1A1. The percentage of participants in the polymorphism categories: wt/wt, wt/\*28, \*28/\*28, \*28/wt, \*28/other and other/other is reported. wt=wild type. \*28 polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression.
Time frame: Cycle 1: Pre-dose
Participants took part in the study at 2 investigative sites in Spain from 22 October 2007 to 05 April 2011.
| Milestone | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D | Alisertib 50 mg QD 14D | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 14 | 6 | 3 | 6 | 7 | 7 | 7 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 3 | 14 | 6 | 3 | 6 | 7 | 7 | 7 |
| Withdrew: Occurrence of adverse event(s) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Unsatisfactory therapeutic response | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 |
| Withdrew: Progressive disease | 3 | 3 | 3 | 12 | 4 | 1 | 3 | 6 | 5 | 5 |
| Withdrew: Patient declined further treatment | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Symptomatic deterioration | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
DLT was evaluated using the National Cancer Institutes Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0; defined as any of the following events related to alisertib therapy: 1. Grade 4 neutropenia lasting for ≥7 consecutive days during recovery 2. Grade 4 neutropenia with fever and/or infection 3. Confirmed platelet count \<25,000/mm\^3 4. ≥Grade 3 nausea and/or emesis despite the use of an antiemetic prophylaxis 5. ≥Grade 3 diarrhea that occurred despite therapy with loperamide 6. Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (\< 1 week) Grade 3 fatigue 7. Treatment delay of \>1 week because of a failure of adequate hematologic or nonhematologic recovery from the previous cycle of treatment. 8. Other alisertib-related nonhematologic toxicities ≥ Grade 2 that, in the opinion of the investigator, required a dose reduction or discontinuation of therapy with alisertib.
| participants | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D | Alisertib 50 mg QD 14D | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicity (DLT) | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 1 | 1 | 3 |
The MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 participants.
| mg BID for 7 Days | Alisertib |
|---|---|
| Maximum Tolerated Dose (MTD) of Alisertib | 50 |
| nanomolar (nM) | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D |
|---|---|---|---|---|---|---|---|
| Day 1 | 123.15 ± 6.554 | 1774.12 ± 36.496 | 2014.81 ± 22.038 | 1035.3 ± 75.70 | 1536.1 ± 44.70 | 1266.6 ± 45.69 | 3196.4 ± 51.11 |
| Day 7 | 109.13 ± 34.458 | 1502.89 ± 32.818 | 4136.24 ± 26.253 | 1964.4 ± 46.26 | 3412.5 ± 27.06 | 5710.4 ± 23.89 | 4694.2 ± 38.86 |
| hour(hr) | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D |
|---|---|---|---|---|---|---|---|
| Day 1 | 1.920 (1.58 to 2.00) | 2.730 (1.70 to 4.00) | 4.000 (2.00 to 5.90) | 2.040 (2.00 to 6.17) | 2.000 (2.00 to 4.08) | 2.000 (2.00 to 2.10) | 3.835 (1.98 to 4.08) |
| Day 7 | 1.670 (1.00 to 1.97) | 1.580 (1.50 to 6.00) | 1.550 (1.42 to 3.43) | 2.000 (1.25 to 8.00) | 2.000 (0.92 to 4.00) | 4.170 (1.75 to 5.83) | 1.580 (1.00 to 6.00) |
| nM*hour(h) | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D |
|---|---|---|---|---|---|---|---|
| Day 1 | 975.0 ± NA | 18204.2 ± 36.19 | 27262.7 ± 38.0 | 6314.1 ± 82.32 | 9771.5 ± 53.77 | 6895.3 ± 9.21 | 16541.5 ± 65.99 |
| Day 7 | 658.5 ± 35.64 | 16101.6 ± 38.81 | 48421.8 ± 36.53 | 17795.6 ± 43.87 | 25853.3 ± 41.44 | 51684.4 ± 24.87 | 40166.7 ± 51.90 |
| hr | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D |
|---|---|---|---|---|---|---|---|
| Terminal Half-Life (t1/2) for Alisertib 7 Day Dosing | — | 18.25 ± 8.697 | 19.80 ± 6.129 | 15.913 ± 6.4766 | 19.475 ± 15.5019 | 18.500 ± 7.6295 | 13.637 ± 6.8712 |
Rac for Day 7=AUCt Day 7/AUCt Day 1.
| ratio | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D |
|---|---|---|---|---|---|---|---|
| Accumulation Ratio (Rac) for Alisertib 7 Day Dosing | 0.874 ± 0 | 0.892 ± 0.1331 | 1.954 ± 0.9092 | 2.295 ± 0.9846 | 2.583 ± 0.8959 | 7.765 ± 1.9163 | 2.350 ± 1.4926 |
| ratio | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D |
|---|---|---|---|---|---|---|---|
| Peak/Trough Ratio for Aliserib 7 Day Dosing | 5.950 ± 0.3253 | 4.650 ± 0.2163 | 4.507 ± 0.3029 | 3.083 ± 2.2296 | 3.050 ± 1.4056 | 1.867 ± 0.6009 | 2.256 ± 1.2013 |
| liter(L)/hr | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D |
|---|---|---|---|---|---|---|---|
| CLss/F: Apparent Oral Clearance at Steady State 7 Day Dosing | 14.055 ± 27.6995 | 9.604 ± 35.5110 | 5.967 ± 31.2592 | 5.414 ± 57.9221 | 4.182 ± 51.2761 | 2.795 ± 23.5794 | 4.798 ± 49.4182 |
| nM | Alisertib 50 mg QD 14D |
|---|---|
| Day 1 | 1145.4 ± 53.09 |
| Day 7 | 1418.1 ± 70.96 |
| Day 14 | 1671.1 ± 51.66 |
| hr | Alisertib 50 mg QD 14D |
|---|---|
| Day 1 | 2.030 (1.00 to 6.00) |
| Day 7 | 2.000 (2.00 to 4.00) |
| Day 14 | 2.000 (1.02 to 4.00) |
| nM*hr | Alisertib 50 mg QD 14D |
|---|---|
| Day 1 | 15363.0 ± 24.82 |
| Day 7 | 17918.8 ± 78.55 |
| Day 14 | 16449.8 ± 59.87 |
| hr | Alisertib 50 mg QD 14D |
|---|---|
| Terminal Half-Life (t1/2) for Alisertib 14 Day Dosing | 26.62 ± 13.611 |
Rac for Day 7=AUCt Day 7/AUCt Day 1. Rac for Day 14=AUCt Day 7/AUCt Day 1.
| ratio | Alisertib 50 mg QD 14D |
|---|---|
| Day 7 | 1.671 ± 0.8242 |
| Day 14 | 1.813 ± 0.5001 |
| ratio | Alisertib 50 mg QD 14D |
|---|---|
| Day 7 | 4.415 ± 2.5016 |
| Day 14 | 7.412 ± 4.2472 |
| L/hr | Alisertib 50 mg QD 14D |
|---|---|
| Day 7 | 5.381 ± 92.8272 |
| Day 14 | 5.856 ± 98.2758 |
| nM | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|
| Day 1 | 1112.3 ± 42.99 | 2220.3 ± 47.57 |
| Day 14 | 1524.1 ± 64.25 | 2595.0 ± 42.98 |
| Day 21 | 1651.7 ± 30.70 | 2093.7 ± 11.68 |
| hr | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|
| Day 1 | 4.000 (2.00 to 6.17) | 2.000 (2.00 to 2.02) |
| Day 14 | 2.070 (1.00 to 4.00) | 2.130 (2.00 to 5.08) |
| Day 21 | 2.100 (2.00 to 24.80) | 2.125 (2.00 to 2.33) |
| nM*hr | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|
| Day 1 | 11701.0 ± 49.78 | 18953.4 ± 56.89 |
| Day 14 | 20262.8 ± 71.34 | 30918.3 ± 55.68 |
| Day 21 | 18264.9 ± 28.67 | 24515.6 ± 23.80 |
| hr | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|
| Terminal Half-Life (t1/2) for Alisertib 21 Day Dosing | 20.13 ± 6.326 | 26.13 ± 9.780 |
Rac for Day 7=AUCt Day 7/AUCt Day 1. Rac for Day 14=AUCt Day 7/AUCt Day 1. Rac for Day 21=AUCt Day 21/AUCt Day 1.
| ratio | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|
| Day 14 | 2.482 ± 2.7166 | 2.103 ± 0.3861 |
| Day 21 | 1.678 ± 0.7587 | 1.933 ± 1.1104 |
| ratio | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|
| Day 14 | 4.070 ± 2.4751 | 3.628 ± 0.4864 |
| Day 21 | 4.792 ± 2.5652 | 4.658 ± 2.1825 |
| L/hr | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|
| Day 14 | 4.753 ± 70.5636 | 4.364 ± 47.3164 |
| Day 21 | 5.276 ± 28.1356 | 5.593 ± 21.8384 |
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
| cells/mm | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D |
|---|---|---|---|---|---|---|---|
| Day 1, 6 Hours Post-Dose | 0.187 ± 0.0709 | 0.107 ± 0.0777 | 0.197 ± 0.0814 | 0.310 ± 0.2087 | 0.378 ± 0.4107 | 0.175 ± 0.2333 | 0.850 ± 1.0741 |
| Day 7, 6 Hours Post-Dose | 0.193 ± 0.1650 | 0.617 ± 0.7514 | 2.703 ± 0.7112 | 3.489 ± 2.6893 | 6.220 ± 5.7549 | 8.757 ± 4.0493 | 9.150 ± 8.9050 |
| Day 7, 24 Hours Post-Dose | 0.140 ± 0.1179 | 0.397 ± 0.2159 | 5.270 ± 3.8325 | 3.184 ± 4.4984 | 1.250 ± 0.0000 | 25.190 ± 1.7678 | 17.123 ± 9.4877 |
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
| cells/mm | Alisertib 50 mg QD 14D |
|---|---|
| Day 1, 6 Hours Post-Dose | 1.180 ± 0.0000 |
| Day 7, 6 Hours Post-Dose | 0.950 ± 0.9963 |
| Day 14, 6 Hours Post-Dose | 1.146 ± 1.6239 |
| Day 7, 24 Hours Post-Dose | 0.368 ± 0.4464 |
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
| cells/mm | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|
| Day 7, 6 Hours Post-Dose | 1.534 ± 1.9201 | 1.900 ± 2.2774 |
| Day 14, 6 Hours Post-Dose | 0.341 ± 0.3182 | 1.168 ± 0.7587 |
| Day 21, 6 Hours Post-Dose | 0.250 ± 1.453 | 0.565 ± 0.5565 |
Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement.
| cells/mm | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D |
|---|---|---|---|---|---|---|---|
| Day 1, 6 hour post-dose | 0.080 ± 0.0693 | 0.000 ± 0.0000 | 0.097 ± 0.0850 | 0.040 ± 0.0634 | 0.000 ± 0.0000 | 0.055 ± 0.0778 | 0.242 ± 0.2566 |
| Day 7, 6 hour post-dose | 0.040 ± 0.0693 | 0.560 ± 0.9699 | 1.303 ± 0.5950 | 1.525 ± 2.2399 | 3.173 ± 4.3170 | 6.040 ± 1.9928 | 5.162 ± 2.2801 |
| Day 7, 24 hour post-dose | 0.040 ± 0.0693 | 0.343 ± 0.4944 | 2.145 ± 1.6476 | 1.050 ± 1.749 | 0.830 ± 0.00 | 7.715 ± 0.1202 | 4.713 ± 1.1924 |
Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement.
| cells/mm | Alisertib 50 mg QD 14D |
|---|---|
| Day 1, 6 hours post-dose | 0.000 ± 0.000 |
| Day 7, 6 hours post-dose | 0.390 ± 0.8721 |
| Day 14, 6 hours post-dose | 0.484 ± 0.7869 |
| Day 14, 24 hours post-dose | 0.260 ± 0.3834 |
Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement.
| cells/mm | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|
| Day 7, 6 hours post-dose | 0.606 ± 0.9954 | 0.379 ± 0.6276 |
| Day 14, 6 hours post-dose | 0.146 ± 0.2355 | 0.404 ± 0.4334 |
| Day 21, 6 hours post-dose | 0.134 ± 0.1698 | 0.230 ± 0.1283 |
Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement.
| percentage of cells | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D |
|---|---|---|---|---|---|---|---|
| Day 1, 6 hours post-dose | 0.125 ± 0.1061 | 0.610 ± 0.0000 | 6.460 ± 9.1075 | 1.464 ± 1.3294 | 1.080 ± 0.3394 | 0.090 ± 0.0000 | 2.907 ± 2.0284 |
| Day 7, 6 hours post-dose | 1.145 ± 0.0354 | 0.590 ± 0.0000 | 15.500 ± 13.5623 | 2.020 ± 2.9567 | 3.115 ± 3.1608 | 5.840 ± 0.0000 | 3.527 ± 2.1258 |
Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement.
| percentage of cells | Alisertib 50 mg QD 14D |
|---|---|
| Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 14 Day Dosing | 0.008 ± 0.0000 |
Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement.
| percentage of cells | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|
| Day 7, 6 hours post-dose | 0.027 ± 0.0171 | 0.050 ± 0.0243 |
| Day 21, 6 hours post-dose | 0.014 ± 0.0072 | 0.054 ± 0.0038 |
A blood sample was collected prior to alisertib dosing for the purpose of genotyping for polymorphisms in UGT1A1. The percentage of participants in the polymorphism categories: wt/wt, wt/\*28, \*28/\*28, \*28/wt, \*28/other and other/other is reported. wt=wild type. \*28 polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression.
| percentage of participants | Alisertib |
|---|---|
| wt/wt | 34 |
| wt/*28 | 44 |
| *28/*28 | 7 |
| *28/wt | 0 |
| *28/other | 0 |
| other/other | 2 |
Collected over Signing of the Informed Consent through 30 days following the last dose of study drug (up to 730 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alisertib 5 mg QD 7D | — | 1/3 (33.3%) | 3/39 (7.7%) |
| Alisertib 80 mg QD 7D | — | 1/3 (33.3%) | 3/30 (10%) |
| Alisertib 150 mg QD 7D | — | 1/3 (33.3%) | 3/101 (3%) |
| Alisertib 50 mg BID 7D | — | 6/14 (42.9%) | 14/142 (9.9%) |
| Alisertib 60 mg BID 7D | — | 3/6 (50%) | 6/68 (8.8%) |
| Alisertib 75 mg BID 7D | — | 1/3 (33.3%) | 3/68 (4.4%) |
| Alisertib 100 mg BID 7D | — | 5/6 (83.3%) | 6/194 (3.1%) |
| Alisertib 50 mg QD 14D | — | 1/7 (14.3%) | 7/119 (5.9%) |
| Alisertib 50 mg QD 21D | — | 3/7 (42.9%) | 7/67 (10.4%) |
| Alisertib 70 mg QD 21D | — | 4/7 (57.1%) | 7/68 (10.3%) |
| Event | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D | Alisertib 50 mg QD 14D | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|---|---|---|---|---|---|---|---|
| StomatitisGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/14 | 0/6 | 0/3 | 3/6 | 0/7 | 0/7 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/14 | 1/6 | 0/3 | 2/6 | 0/7 | 0/7 | 1/7 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 1/14 | 1/6 | 0/3 | 2/6 | 0/7 | 0/7 | 0/7 |
| LymphadenopathyBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 0/14 | 0/6 | 1/3 | 0/6 | 0/7 | 0/7 | 0/7 |
| Spinal cord compressionNervous system disorders | 0/3 | 1/3 | 0/3 | 0/14 | 0/6 | 0/3 | 0/6 | 0/7 | 0/7 | 0/7 |
| Incorrect dose administeredInjury, poisoning and procedural complications | 0/3 | 0/3 | 1/3 | 0/14 | 0/6 | 0/3 | 0/6 | 0/7 | 0/7 | 0/7 |
| Renal failureRenal and urinary disorders | 1/3 | 0/3 | 0/3 | 0/14 | 0/6 | 0/3 | 0/6 | 1/7 | 0/7 | 0/7 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/14 | 0/6 | 0/3 | 1/6 | 0/7 | 0/7 | 0/7 |
| VomitingGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/14 | 0/6 | 0/3 | 1/6 | 0/7 | 0/7 | 0/7 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 0/14 | 0/6 | 0/3 | 1/6 | 0/7 | 0/7 | 0/7 |
| Event | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D | Alisertib 50 mg QD 14D | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D |
|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/3 | 2/3 | 2/3 | 8/14 | 4/6 | 3/3 | 5/6 | 5/7 | 4/7 | 1/7 |
| LeukopeniaBlood and lymphatic system disorders | 0/3 | 1/3 | 2/3 | 8/14 | 3/6 | 2/3 | 6/6 | 2/7 | 1/7 | 4/7 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 1/3 | 3/3 | 4/14 | 4/6 | 2/3 | 3/6 | 2/7 | 3/7 | 2/7 |
| AstheniaGeneral disorders | 3/3 | 0/3 | 2/3 | 3/14 | 3/6 | 2/3 | 5/6 | 3/7 | 6/7 | 4/7 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/3 | 2/3 | 3/3 | 1/14 | 4/6 | 2/3 | 4/6 | 1/7 | 3/7 | 5/7 |
| LymphopeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 2/3 | 9/14 | 2/6 | 1/3 | 0/6 | 6/7 | 2/7 | 0/7 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 1/3 | 2/3 | 5/14 | 2/6 | 1/3 | 5/6 | 2/7 | 0/7 | 1/7 |
| PyrexiaGeneral disorders | 0/3 | 0/3 | 1/3 | 1/14 | 1/6 | 1/3 | 5/6 | 4/7 | 1/7 | 2/7 |
| NauseaGastrointestinal disorders | 1/3 | 0/3 | 2/3 | 1/14 | 2/6 | 1/3 | 4/6 | 2/7 | 3/7 | 5/7 |
| SomnolenceNervous system disorders | 1/3 | 2/3 | 2/3 | 4/14 | 2/6 | 1/3 | 3/6 | 0/7 | 1/7 | 5/7 |
Safety population was defined as all participants who received any amount of study drug.
| Age, Continuous(years) | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D | Alisertib 50 mg QD 14D | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 52.7 ± 9.07 | 62.3 ± 13.80 | 55.7 ± 20.79 | 62.5 ± 11.67 | 59.2 ± 18.74 | 48.3 ± 14.84 | 58.7 ± 8.69 | 58.0 ± 13.83 | 53.0 ± 11.08 | 64.7 ± 5.53 | 58.8 ± 12.46 |
| Sex: Female, Male(Participants) | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D | Alisertib 50 mg QD 14D | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 1 | 2 | 6 | 4 | 0 | 2 | 2 | 3 | 2 | 22 |
| Male | 3 | 2 | 1 | 8 | 2 | 3 | 4 | 5 | 4 | 5 | 37 |
| Race/Ethnicity, Customized(participants) | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D | Alisertib 50 mg QD 14D | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic/Latino | 3 | 3 | 3 | 14 | 6 | 3 | 6 | 7 | 6 | 5 | 56 |
| Not Hispanic/Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
| Race/Ethnicity, Customized(participants) | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D | Alisertib 50 mg QD 14D | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number | 3 | 3 | 3 | 14 | 6 | 3 | 6 | 7 | 7 | 7 | 59 |
| Region of Enrollment(participants) | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D | Alisertib 50 mg QD 14D | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Spain | 3 | 3 | 3 | 14 | 6 | 3 | 6 | 7 | 7 | 7 | 59 |
| Height(cm) | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D | Alisertib 50 mg QD 14D | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 164.0 ± 7.21 | 164.3 ± 10.79 | 167.3 ± 1.53 | 165.8 ± 9.26 | 160.5 ± 4.76 | 171.3 ± 10.26 | 165.2 ± 10.21 | 169.9 ± 10.92 | 160.4 ± 11.57 | 167.6 ± 8.40 | 165.4 ± 9.15 |
| Weight(kg) | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D | Alisertib 50 mg QD 14D | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 83.7 ± 32.13 | 75.2 ± 10.56 | 70.3 ± 4.24 | 74.4 ± 16.48 | 64.8 ± 6.83 | 90.5 ± 7.74 | 69.6 ± 16.22 | 76.7 ± 15.06 | 69.1 ± 14.78 | 77.9 ± 11.91 | 74.0 ± 14.95 |
| Body Surface Area (BSA)(m^2) | Alisertib 5 mg QD 7D | Alisertib 80 mg QD 7D | Alisertib 150 mg QD 7D | Alisertib 50 mg BID 7D | Alisertib 60 mg BID 7D | Alisertib 75 mg BID 7D | Alisertib 100 mg BID 7D | Alisertib 50 mg QD 14D | Alisertib 50 mg QD 21D | Alisertib 70 mg QD 21D | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 1.93 ± 0.393 | 1.85 ± 0.191 | 1.81 ± 0.047 | 1.85 ± 0.225 | 1.70 ± 0.102 | 2.07 ± 0.098 | 1.78 ± 0.244 | 1.87 ± 0.204 | 1.75 ± 0.231 | 1.90 ± 0.145 | 1.84 ± 0.208 |
Ran from Oct 2007 to primary completion in Sep 2010, 34 months.
Results were first posted in Mar 2019, 8 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Millennium Pharmaceuticals, Inc. →